CPS
The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA (pembrolizumab)
Presenter:
Dr. Kristopher Kersch, MD, Pathologist, Agilent Technologies
Presenter:
Dr. Kristopher Kersch, MD, Pathologist, Agilent Technologies